LENZ

LENZ Therapeutics, Inc. - 10-Q Summary (Q1 2026)

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. LENZ Therapeutics, Inc. is a commercial pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for the treatment of presbyopia. The product received FDA approval on July 31, 2025, and commercial launch in the U.S. began in August 2025. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Revenue Breakdown (Q1 2026): Product sales, net were $1.7 million; License revenue was $0.25 million.

Expense Breakdown (Q1 2026): Selling, general and administrative (SG&A) expenses were $45.0 million; Cost of sales was $1.1 million; Research and development (R&D) expenses were $0.

Material Changes vs. Prior Period

• Revenue Generation: The company transitioned from zero revenue in Q1 2025 to $1.9 million in Q1 2026, driven by the commercial launch of VIZZ and a new distribution agreement.
• SG&A Increase: SG&A expenses increased by $33.8 million (305%) year-over-year. This was primarily due to a $17.2 million increase in commercial marketing and advertising (including a DTC campaign launched in January 2026), $12.8 million in increased employee salaries/headcount for the sales force, and reclassification of certain regulatory and quality costs from R&D to SG&A following FDA approval.
• R&D Decrease: R&D expenses decreased by $5.8 million (100%) as the company ceased clinical trial activities following FDA approval. Costs previously classified as R&D are now capitalized to inventory or classified as SG&A.
• Cost of Sales: Cost of sales of $1.1 million included nonrecurring charges for inventory write-offs due to a temperature excursion during transit and packaging write-offs related to a manufacturing transition.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes existing cash, cash equivalents, and marketable securities of $258.4 million are sufficient to fund operations for at least the next 12 months and to reach positive operating cash flow. The company expects to continue incurring significant expenses related to commercialization, marketing, and manufacturing.

Recent Developments:

• Submitted Marketing Authorization Applications (MAA) to the European Medicines Agency (EMA) in March 2026 and the UK's MHRA in April 2026.
• Entered into a distribution agreement with Lunatus Global Medical Supplies for the Middle East in January 2026, generating $0.25 million in license revenue.

Risks and Contingencies:

• Market Acceptance: Success depends entirely on VIZZ. The company faces competition from Vuity, Qlosi, and Yuvezzi. Market acceptance may be hindered by patient experiences with prior miotic products.
• Manufacturing Reliance: The company relies entirely on third-party manufacturers. Disruptions or quality issues could impair supply.
• Capital Requirements: While current liquidity is sufficient, the company may require additional financing if commercialization costs exceed expectations or revenue growth is slower than anticipated.
• Regulatory: Ongoing regulatory oversight and potential changes in healthcare legislation (e.g., drug pricing reforms) could impact profitability.

Investor Verification Checklist

• Commercial Trajectory: Verify the rate of prescription fills and refill rates for VIZZ to assess market adoption against the $3 billion U.S. market opportunity estimate.
• Marketing Efficiency: Monitor the return on investment for the new direct-to-consumer (DTC) marketing campaign and the expansion of the sales force to 117 territories.
• Inventory Management: Review future cost of sales trends as "zero-cost" inventory (capitalized pre-approval) is depleted, which will increase per-unit costs.
• International Expansion: Track the status of regulatory submissions in Europe (EMA) and the UK (MHRA) and the performance of license partners in Greater China, Southeast Asia, Canada, and the Middle East.
• Liquidity Runway: Confirm the burn rate relative to the $258.4 million cash position to validate the 12-month liquidity assertion.